Janssen and Bayer report real-world data supporting Xarelto

Janssen and Bayer have reported new real-world data that demonstrates the benefits Xarelto can offer in the treatment of venous thromboembolism (VTE).

The two new studies have confirmed the positive benefit-risk profile of the novel oral anticoagulant in treating VTE, or blood clots, while also reducing the risk of recurrence.

In the first study, which involved nearly 5,000 patients, people with VTE taking Xarelto for longer than three months were shown to have a lower risk of VTE recurrence without an increase in major bleeding, compared to those taking the medicine for only three months.

Meanwhile, early data from Janssen's post-marketing safety surveillance study showed that rates and patterns of major bleeding in people taking Xarelto for VTE in routine clinical practice were consistent with those reported in clinical trials.

Dr Paul Burton, vice-president for medical affairs at Janssen, said: "These results add to a rapidly growing body of real-world research for Xarelto and, specifically in the case of VTE, reaffirm the results observed in our landmark EINSTEIN clinical trial programme."

To date, more than 91,000 people have been enrolled in real-world studies for Xarelto across all six approved indications.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.